Imatinib Imat 400mg Tablets

Get a Price/Quote

MOQ : 10 Packs

Imatinib Imat 400mg Tablets Specification

Indication
Chronic Myeloid Leukemia (CML), Gastrointestinal Stromal Tumors (GIST), certain other cancers

Dosage Form
Tablet

Salt Composition
Imatinib Mesylate 400mg

Feature
Oral tablet, targeted therapy, once daily dosing

Ingredients
Imatinib Mesylate, Excipients

Application
Used as an antineoplastic agent for the treatment of cancers

Physical Color/Texture
Tablet, likely white or off-white

Storage Instructions
Store below 30C, protect from moisture

Shelf Life
24 to 36 months (refer to packaging for exact expiry)

Brand Name
Imat 400

Route of Administration
Oral

Contraindications
Pregnancy, certain allergies; consult physician

Prescription
Required

Packaging
Box of 30 tablets

Strength
400mg per tablet

Market Approval
Available in multiple international markets

Patient Group
Adults (pediatric usage per doctor's discretion)

Caution
To be used under medical supervision only

Drug Class
Tyrosine kinase inhibitor

Imatinib Imat 400mg Tablets About

Imat 400 Tablets (Imatinib Imat 400mg) stand as a paragon of targeted therapy for patients battling Chronic Myeloid Leukemia (CML), Gastrointestinal Stromal Tumors (GIST), and other select malignancies. Procure this cost-effective, redoubtable medication - crafted for adult patients and offered in a convenient box of 30 tablets, each delivering 400mg Imatinib Mesylate. With noteworthy global market approval, Imat 400 must only be used under expert medical supervision. Try now for an effective, once-daily oral solution with assured quality from India's leading manufacturer.

Imat 400mg Tablets: Special Features & Ideal Applications

Imat 400 showcases advanced targeted therapy, distinguishing itself as a noteworthy oral oncological treatment. Designed primarily for adults, this formulation is beneficial in tackling CML, GIST, and certain other cancers. Its once-daily direct oral administration enhances patient compliance and convenience. Imat 400 is particularly suited for use in hospitals, clinics, and oncology treatment centers, making it indispensable for healthcare providers striving for effective cancer management. Always administer under strict physician supervision for optimal safety and results.

Main Export Markets & Packaging: Imat 400mg Tablets

Offered at a competitive sale price, Imat 400mg Tablets are regularly shipped goods to prominent international markets, particularly in Europe, Asia, and Africa. Each box handed over to clients contains 30 tablets, securely packaged for transit, retaining efficacy and safety during transportation. The main domestic market in India benefits from widespread availability, owing to reliable supply chains and strategic partnerships with distributors, ensuring timely delivery to pharmacies and healthcare facilities nationwide.

FAQ's of Imatinib Imat 400mg Tablets:

Q: How should Imat 400 Tablets be administered for optimal effectiveness?

A: Imat 400 Tablets should be taken orally once daily with a glass of water, preferably at the same time each day to maintain steady drug levels. Always follow your physician's specific instructions regarding dosage and timing.

Q: What conditions are Imatinib Imat 400mg Tablets indicated for?

A: Imatinib Imat 400mg is indicated for the treatment of Chronic Myeloid Leukemia (CML), Gastrointestinal Stromal Tumors (GIST), and select other malignancies, as directed by a healthcare professional.

Q: When is caution required while using Imat 400 Tablets?

A: Caution is required during pregnancy, breastfeeding, and in patients with certain allergies. Imat 400 Tablets must not be used in these scenarios without explicit medical consultation.

Q: Where can Imat 400mg Tablets be sourced internationally?

A: Imat 400mg Tablets are available for procurement in multiple international markets across Europe, Asia, and Africa, reflecting their global market approval and wide distribution network.

Q: What are the benefits of choosing Imat 400 over alternatives?

A: Imat 400 offers a cost-effective, targeted therapeutic approach, enhanced patient compliance with once-daily dosing, and a robust safety profile, making it a compelling choice for both clinicians and patients in cancer management.

Tell us about your requirement